Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: More common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression

• Published in: Cancer research (Chicago, Ill.) Vol. 63; no. 16; pp. 4842 - 4848
• Main Authors: PULLING, Leah C, DIVINE, Kevin K, KLINGE, Donna M, GILLILAND, Frank D, KANG, Terri, SCHWARTZ, Ann G, BOCKLAGE, Therese J, BELINSKY, Steven A
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.08.2003
• Subjects: Adenocarcinoma - etiology; Adenocarcinoma - genetics; Adult; Aged; Biological and medical sciences; Codon; DNA Methylation; Female; Genes, ras; Humans; Lung Neoplasms - etiology; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Mutation; O-Methylguanine-DNA Methyltransferase - genetics; Pneumology; Prognosis; Promoter Regions, Genetic; Smoking - adverse effects; Tumors of the respiratory system and mediastinum; Adenocarcinoma; Human; Lung disease; Nucleotide sequence; Respiratory disease; Enzyme; Transcription promoter; Transferases; Tobacco smoking; Malignant tumor; CpG island; Bronchopulmonary; Non smoker; Methylated-DNA-protein-cysteine S-methyltransferase; Gene silencing; Methyltransferases; GC rich sequence; Smoker; DNA; Tumor progression; Bronchus disease; Mutation; Methylation; Comparative study
• ISSN: 0008-5472; 1538-7445

Adenocarcinoma (AC) is the most common type of lung cancer diagnosed in the United States, comprising up to 40% of tumors in smokers and 50-80% of tumors in never-smokers. Exposures to cigarette smoke, direct or second-hand, and radiation in the form of radon progeny are the major risk factors for lung AC in both smokers and never-smokers. The goal of the current study was to determine the prevalence for O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in a large sample of central or peripheral ACs from smokers (n = 157), former uranium miners (n = 34), and never-smokers (n = 46). The mutation rate at codon 12 of the K-ras gene was determined to assess whether activation of this oncogene was associated with MGMT methylation. The overall prevalence for MGMT methylation was 51%. Significantly more tumors from never-smokers than smokers exhibited MGMT methylation (66 versus 47%, respectively). In contrast, exposure to radon through uranium mining did not affect the prevalence for methylation. The frequency of MGMT methylation was increased significantly in association with tumor stage. K-ras mutations were detected in 24% of all ACs and 22, 24, and 28% of tumors from never-smokers, smokers, and miners, respectively. Alterations in both the K-ras and MGMT genes were seen in only 11% of ACs. Kaplan-Meier survival estimates did not reveal any difference between patient survival with or without MGMT methylation. In contrast, survival was significantly reduced over the initial 60 months after diagnosis for patients with a transition mutation in the K-ras gene compared with those with a transversion mutation. This investigation demonstrates that MGMT promoter hypermethylation is a common event in the progression of early stage AC of the lung. We have shown that the incidence of MGMT methylation was significantly higher in never-smokers than smokers and have detected a higher frequency of mutations within the K-ras gene than previously reported in never-smokers. This study also suggests that K-ras activation is independent of MGMT methylation.